| Involvement of the mismatch repair system in temozolomide-induced apoptosis S D’Atri, L Tentori, PM Lacal, G Graziani, E Pagani, E Benincasa, ... Molecular pharmacology 54 (2), 334-341, 1998 | 352 | 1998 |
| EGFR heterogeneity and implications for therapeutic intervention in glioblastoma E Eskilsson, GV Rĝsland, G Solecki, Q Wang, PN Harter, G Graziani, ... Neuro-oncology 20 (6), 743-752, 2018 | 280 | 2018 |
| A region of proto-dbl essential for its transforming activity shows sequence similarity to a yeast cell cycle gene, CDC24, and the human breakpoint cluster gene, bcr. D Ron, M Zannini, M Lewis, RB Wickner, LT Hunt, G Graziani, SR Tronick, ... The New Biologist 3 (4), 372-379, 1991 | 263 | 1991 |
| Systemic administration of GPI 15427, a novel poly (ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma … L Tentori, C Leonetti, M Scarsella, G d’Amati, M Vergati, I Portarena, W Xu, ... Clinical Cancer Research 9 (14), 5370-5379, 2003 | 262 | 2003 |
| Chemopotentiation by PARP inhibitors in cancer therapy L Tentori, G Graziani Pharmacological research 52 (1), 25-33, 2005 | 259 | 2005 |
| Potential clinical applications of poly (ADP-ribose) polymerase (PARP) inhibitors L Tentori, I Portarena, G Graziani Pharmacological research 45 (2), 73-85, 2002 | 243 | 2002 |
| Experimental evidence of the antitumor, antimetastatic and antiangiogenic activity of ellagic acid C Ceci, PM Lacal, L Tentori, MG De Martino, R Miano, G Graziani Nutrients 10 (11), 1756, 2018 | 222 | 2018 |
| Role of BRCA mutations in cancer treatment with poly (ADP-ribose) polymerase (PARP) inhibitors I Faraoni, G Graziani Cancers 10 (12), 487, 2018 | 216 | 2018 |
| Clinical perspectives of PARP inhibitors G Graziani, C Szabó Pharmacological research 52 (1), 109-118, 2005 | 200 | 2005 |
| Role of VEGFs/VEGFR-1 signaling and its inhibition in modulating tumor invasion: experimental evidence in different metastatic cancer models C Ceci, MG Atzori, PM Lacal, G Graziani International journal of molecular sciences 21 (4), 1388, 2020 | 193 | 2020 |
| Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer G Graziani, L Tentori, P Navarra Pharmacological research 65 (1), 9-22, 2012 | 189 | 2012 |
| Poly (ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis L Tentori, PM Lacal, A Muzi, AS Dorio, C Leonetti, M Scarsella, F Ruffini, ... European Journal of Cancer 43 (14), 2124-2133, 2007 | 183 | 2007 |
| Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive … PM Lacal, G Graziani Pharmacological research 136, 97-107, 2018 | 166 | 2018 |
| Role of beauty treatment in the spread of parenterally transmitted hepatitis viruses in Italy A Mariano, A Mele, ME Tosti, A Parlato, G Gallo, P Ragni, C Zotti, ... Journal of medical virology 74 (2), 216-220, 2004 | 146 | 2004 |
| PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy E Salvati, M Scarsella, M Porru, A Rizzo, S Iachettini, L Tentori, G Graziani, ... Oncogene 29 (47), 6280-6293, 2010 | 136 | 2010 |
| Challenging resistance mechanisms to therapies for metastatic melanoma L Tentori, PM Lacal, G Graziani Trends in pharmacological sciences 34 (12), 656-666, 2013 | 134 | 2013 |
| Alternative splicing generates at least five different isoforms of the human basic-FGF receptor. A Eisemann, JA Ahn, G Graziani, SR Tronick, D Ron Oncogene 6 (7), 1195-1202, 1991 | 129 | 1991 |
| Inhibition of poly (ADP‐ribose) polymerase prevents irinotecan‐induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma L Tentori, C Leonetti, M Scarsella, A Muzi, E Mazzon, M Vergati, O Forini, ... The FASEB journal 20 (10), 1709-1711, 2006 | 122 | 2006 |
| Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? L Tentori, G Graziani Pharmacological Research 55 (5), 359-369, 2007 | 118 | 2007 |
| EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation E Eskilsson, GV Rosland, KM Talasila, S Knappskog, O Keunen, ... Neuro-oncology 18 (12), 1644-1655, 2016 | 113 | 2016 |
